



**PHARMACY AND THERAPEUTICS COMMITTEE
ACA/Exchange MEETING MINUTES
October 30, 2025**

Attendance: Microsoft Teams Meeting
 Gary Bledsoe, Staff/Clinical Pharmacist; Dr. Edgar Chou, Jefferson Health; Jerry Crawford, Staff/Clinical Pharmacist; Dr. Neal Demp, Community Behavior Health; Danielle Dolores, Director Pharmacy Services; Dr. George E. Downs, Dean Emeritus and Professor, St. Joseph's University; Leah Finken, Clinical Programs Pharmacist; Sharon Ford, Staff/Clinical Pharmacist; Hailey Fry, Centennial Pharmacy; Paul Goebel, Assistant Director Pharmacy, Jefferson Enterprise; Dr. Merleen Harris-Williams, Medical Director; Yelena Hedrick, Staff/Clinical Pharmacist; Gia Ho, Pharmacy Resident; Jessica (Tran) Hoang-Le, Staff/Clinical Pharmacist; Samantha Jackson, Formulary Pharmacist; Lawrence Jones, Retired Executive Director, Pennsylvania Society of Health-System Pharmacists (PSHP); Kaylei Koerwitz, Manager Pharmacy Operations and Clinical Programs; Dr. Tania Kolev, Medical Director; Hannah McCaffrey, Manager Pharmacy Regulations & Implementations; Lisa Murray, Staff/Clinical Pharmacist; Maryana Prokopets, Staff/Clinical Pharmacist; Kateryna Puia, Clinical Programs Pharmacist; Sara Sadiq, Staff/Clinical Pharmacist; Heather Scheckner, Clinical Pharmacist, Jefferson Health; Mike Smikovecus, Staff/Clinical Pharmacist; Robert Spencer, Staff/Clinical Pharmacist; Shelley Staffa, Clinical Pharmacist; Justin Steffan, Staff/Clinical Pharmacist; Brian Swift, Enterprise Vice President/Chief Pharmacy Officer, Jefferson Health; Fallan Vaisberg, Formulary Pharmacist; Jeanine Zubrzycki, Staff/Clinical Pharmacist

Excused: Dr. Paul Aitken, Medical Director; Dr. Rick Buzard, Associate Chief Medical Officer; Connie Chan, Staff/Clinical Pharmacist; Dr. Demian Elder, Medical Director; Ruth John, Staff/Clinical Pharmacist; Brandi Mahler, Supervisor Pharmacy Technicians; Sanjiv Raj, Associate VP Customer Engagement; Julie Samuel, Clinical Programs Pharmacist; Dr. Chris Squillaro, Medical Director, Magellan Behavioral Health

Minutes taken by: Joana Iverson

I. Administrative Update

TOPIC	DISCUSSION	ACTIONS	RESPONSIBLE PARTY	RESOLVED/ PENDING
Minutes Review/Approval	D. Dolores presented the minutes from the August 2025 meeting to the Committee for review.	The Committee approved the minutes from our last meeting as presented.	D. Dolores	Resolved
Policies and Procedures	D. Dolores reviewed the policies and procedure updates. - Pharmacy Prior Authorization - Pharmacy Operations and Responsibilities - Pharmacy Formulary Management	The Committee approved the procedures as presented.	D. Dolores	Resolved

TOPIC	DISCUSSION	ACTIONS	RESPONSIBLE PARTY	RESOLVED/ PENDING
	• <i>JHP Pharmacy Vendor Management</i> • <i>Pharmacy and Therapeutics (P&T) Committee</i> • <i>Drug Utilization Review</i>			

II. 2026 Drug Formulary Review/Update

TOPIC	DISCUSSION	ACTIONS	RESPONSIBLE PARTY	RESOLVED/ PENDING
2026 Prior Authorization Criteria Review	The Committee reviewed the 2026 Prior Authorization Criteria. The Committee approved as presented. • <i>Nucala (NF)</i> • <i>Xyrem/Xywav</i>	<i>The Committee approved as presented.</i>	<i>H. McCaffrey</i>	<i>Resolved</i>
2026 Formulary Additions	The Committee reviewed the 2026 Formulary Additions. • <i>Dapagliflozin tablet - T3, QL 30/30 days</i> • <i>Dapagliflozin-metformin 5-1000 MG ER tablet - T3, QL 60/30 days</i> • <i>Dapagliflozin-metformin 10-1000 MG ER tablet - T3, QL 30/30 days</i> • <i>Jaythari tablet - T4, PA</i> • <i>Jubbonti 60 mg/mL prefilled syringe - T4, PA, QL 1/180 days</i> • <i>Pyqui 22.75 mg/mL suspension - T4, PA, QL 52/30 days</i> • <i>Wyost 120 mg/1.7 mL solution - T5, PA</i>	<i>The Committee approved as presented.</i>	<i>F. Vaisberg</i>	<i>Resolved</i>

III. 2025 Drug Formulary Review/Update

2025 Formulary Additions	The Committee reviewed the 2025 Formulary Additions. The Committee approved as presented. • <i>Bosentan 32 mg soluble tablet - T5, PA, QL 120/30 days</i> • <i>Brimonidine tartrate 0.1 % solution - T2</i> • <i>Brukinsa 160 mg tablet - T5, PA</i> • <i>Comirnaty 5-11 years 10 mcg/0.3mL suspension - T0</i> • <i>Dabigatran etexilate mesylate 110 mg capsule - T2, QL 60/30 days</i> • <i>Dexcom G7 15-day sensor - T3, PA, QL 2/30 days</i> • <i>Doptelet 10 mg sprinkle capsule - T5, PA, QL 60/30 days</i>	<i>The Committee approved as presented.</i>	<i>F. Vaisberg</i>	<i>Resolved</i>
---------------------------------	---	---	--------------------	-----------------

	• <i>Hernexeos 60 mg tablet - T5, PA, QL 90/30 days</i> • <i>Jaythari tablet - T5, PA</i> • <i>Koselugo 5, 7.5 mg sprinkle capsule - T5, PA</i> • <i>Liomny 5, 25, 50 mcg tablet - T2</i> • <i>Luizza 1.5-30 mg-mcg tablet - T0</i> • <i>Luizza 1-20 mg-mcg tablet - T0</i> • <i>Modeyso 125 mg capsule - T5, PA, 20/28 days</i> • <i>Nuvaxovid COVID-19 vaccine 5 mcg/0.5mL - T0</i> • <i>Otezla XR 75 mg tablet - T5, PA</i> • <i>Otezla/Otezla XR initiation pack 0&20&30&(ER)75 mg - T5, PA</i> • <i>Prezcobix 675-150 mg tablet - T4, QL 30/30 days</i> • <i>Pyqui 22.75 mg/mL suspension - T5, PA QL 52/30 days</i> • <i>Rivaroxaban 2.5 mg tablet - T3, QL 60/30 days</i> • <i>Rivaroxaban 1 mg/mL suspension - T3, QL 620/30 days</i> • <i>Valtya 1/35 1-35 mg-mcg tablet - T0</i> • <i>Zelvysia 100 mg, 500 mg packet - T5, PA</i>			
2025 Quantity Limit Additions	<i>The Committee reviewed the 2025 Quantity Limit Additions. The Committee approved as presented.</i> • <i>Byetta 10 mcg/0.04mL pen - 2.4 mL/30 days</i> • <i>Byetta 5 mcg/0.02mL pen - 1.2 mL/30 days</i> • <i>Mounjaro autoinjector - 2 mL/28 days</i> • <i>Rybelsus tablet - 30/30 days</i> • <i>Saxenda 18 mg/3mL pen - 15 mL/30 days</i> • <i>Victoza 18 mg/3mL pen - 9 mL/30 days</i> • <i>Wegovy 0.25, 0.5, 1 mg/0.5mL autoinjector - 2 mL/28 days</i> • <i>Wegovy 1.7 mg/0.75mL autoinjector - 3 mL/28 days</i> • <i>Wegovy 2.4 mg/0.75mL autoinjector - 3 mL/28 days</i> • <i>Zepbound autoinjector - 2 mL/28 days</i>	<i>The Committee approved as presented.</i>	<i>F. Vaisberg</i>	<i>Resolved</i>
Prior Authorization Updates	<i>The Committee reviewed the Prior Authorization criteria and approved as presented.</i> <i>No clinical updates:</i> • <i>Analgesics Opioid Long-Acting</i> • <i>Analgesics Opioid Short-Acting</i> • <i>Bexarotene gel</i> • <i>Early Refills</i> • <i>Lanreotide Extended Release (NF)</i> • <i>Ledipasvir-velpatasvir and Harvoni</i>	<i>The Committee reviewed the Prior Authorization criteria and approved as presented.</i>	<i>F. Vaisberg</i> <i>J. Steffan</i> <i>J. Zubrzycki</i> <i>G. Bledsoe</i> <i>S. Sadiq</i> <i>R. Spencer</i> <i>S. Jackson</i>	<i>Resolved</i>


	• <i>Miglustat</i> • <i>Pegasys</i> • <i>Pulmozyme</i> • <i>Quantity Limits</i> • <i>Sofosbuvir-velpatasvir and Epclusa</i> • <i>Sovaldi</i> • <i>Vosevi</i> • <i>Zepatier</i> <i>Criteria updated:</i> • <i>Evrysdi</i> • <i>Fasenra</i> • <i>Sivextro</i> • <i>Rezdiffra</i> • <i>Tolvaptan</i> • <i>Repatha</i> • <i>Non-Formulary Exceptions Criteria and Tiering Policy</i> • <i>Mifepristone 300 mg tablet</i> • <i>Rinvoq</i> • <i>Strensiq</i> • <i>Xeljanz</i> • <i>Zepbound</i>			
IV. New Drug Review	<i>(Presented in New Drug Review for Medicare.)</i> <i>The following new Protected Class Drugs were reviewed and will be added to the formulary per CMS regulations:</i> • <i>Libtayo (cemiplimab-rwlc) Injection</i> • <i>Zepzelca (lurbinectedin) Injection</i> • <i>Inluriyo (imlunestrant) Tablets*</i> • <i>Keytruda Qlex (pembrolizumab and berahyaluronidase alfa-pmph) Injection*</i> • <i>Koselugo (selumetinib) Capsules</i> • <i>Inlexzo (gemcitabine) intravesical system - formerly TAR-200*</i> • <i>Hernexeos (zongertinib) Tablets*</i> • <i>Modeyso (dordaviprone) Capsules*</i> • <i>Biktarvy (bictegravir, emtricitabine and tenofovir alafenamide) Tablets</i> <i>The following medications are Formulary with new FDA-approved indications:</i>	<i>The Committee approved the New Drug Review as presented and recommended.</i>	<i>G. Ho</i>	<i>Resolved</i>

	• <i>mNEXSPIKE (COVID-19 Vaccine, mRNA) Injection</i> • <i>Nuvaxovid (COVID-19 Vaccine, Adjuvanted) Injectable Suspension</i> • <i>Comirnaty (COVID-19 Vaccine, mRNA) Injection</i> • <i>Repatha (evolocumab) Injection</i> • <i>Doptelet (avatrombopag) Tablets and Oral Granules</i> <i>The following medications were reviewed and will be kept as Non-formulary. Prior Authorization criteria will be developed as needed:</i> • <i>Simponi (golimumab) Injection</i> • <i>Jascayd (nerandomilast) Tablets*</i> • <i>Lasix ONYU (furosemide) Injection*</i> • <i>Zoryve (roflumilast) Cream and Foam</i> • <i>Rhapsido (remibrutinib) Tablets*</i> • <i>Enoby (denosumab-qbde) Injection*</i> • <i>Qivigy (immune globulin intravenous, human-kthm) Solution for Infusion*</i> • <i>Clotic (clotrimazole) Otic Solution*</i> • <i>Xtrenbo (denosumab-qbde) Injection*</i> • <i>Palsonify (paltusotine) Tablets*</i> • <i>Bondlido (lidocaine) Topical System*</i> • <i>Evkeeza (evinacumab-dgnb) Injection</i> • <i>Tremfya (guselkumab) Injection</i> • <i>Forzinity (elamipretide hydrochloride) Injection*</i> • <i>Opzelura (ruxolitinib) Cream</i> • <i>Enbumyst (bumetanide) Nasal Spray*</i> • <i>Vonvendi (von willebrand factor (recombinant)) for Injection</i> • <i>Leqembi (lecanemab-irmb) Injection</i> • <i>Wayrilz (rilzabrutinib) Tablets*</i> • <i>Filspari (sparsentan) Tablets</i> • <i>Dawnzera (donidalorsen) Injection*</i> • <i>Wegovy (semaglutide) Injection</i> • <i>Tonmya (cyclobenzaprine hydrochloride) - formerly TNX-102 SL*</i> • <i>Papzimeos (zopapogene imadenovec-drba) Injection*</i> • <i>Brinsupri (brensocatib) Tablets*</i> • <i>KETARx (ketamine hydrochloride) Injection*</i> • <i>Ajovy (fremanezumab-vfrm) Injection</i> • <i>Alhemo (concizumab-mtci) Injection</i>			
--	---	--	--	--

	• <i>Leqvio (inclisiran) Injection</i> • <i>Vizz (aceclidine) Ophthalmic Solution - formerly LN2100*</i> • <i>Aytozma (tocilizumab-anoh) Injection</i> • <i>Empaveli (pegcetacoplan) Injection</i> • <i>Sephience (sepiapterin) Oral Powder*</i> • <i>Skytrofa (lonapegsomatropin-tcgd) Lyophilized Powder for Injection</i> • <i>Vostally (ramipril) Oral Solution*</i> (* Previously discussed in New Drug Review for Medicaid)			
--	--	--	--	--

V. Adjournment

There being no further business to discuss, the meeting was adjourned. Next meeting is to be held February 2026.



11/14/2025

Danielle Dolores, Director of Pharmacy Services

Date